Home > News > Q10: Stuart Hendry, CEO at Sphere Medical
September 5th, 2007
Q10: Stuart Hendry, CEO at Sphere Medical
Abstract:
Sphere, which was founded in 2002, is combining its patented microtechnology and nanotechnology to develop unique dice-sized microanalysers capable of measuring several key compounds such as, glucose, blood gases and drugs, simultaneously at low cost. Mortality in critical care remains unacceptably high, with associated costs of £billions annually. Real time measurement of drugs and physiological parameters, facilitating tight control of therapy, has been shown to dramatically improve patient outcomes, saving lives and money. Unfortunately, cost effective products to achieve this ideal are not currently available.
Source:
businessweekly.co.uk
Bookmark:
Nanomedicine
Nanoparticle Harnesses Powerful Radiation Therapy for Cancer May 20th, 2013
Microneedle-Delivered Nanoparticles Boost Antitumor Vaccines May 20th, 2013
New Nanopore Sensor Simplifies Analysis of Methylated DNA May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals
Nanoparticle Delivers Large Protein Complex to Cancer Cell Nucleus May 20th, 2013
Protein 'Passport' Helps Nanoparticles Get Past Immune System May 20th, 2013
Nanoparticle Harnesses Powerful Radiation Therapy for Cancer May 20th, 2013
Microneedle-Delivered Nanoparticles Boost Antitumor Vaccines May 20th, 2013